{"success":true,"data":{"pressRelease":{"id":"136588","rtpr_id":"nPn2ZKBnna-20260907","ticker":"1672","exchange":"HKEX","all_tickers":["1672"],"title":"Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs","author":"PR Newswire","published_at":"2026-09-07T04:15:00.622Z","article_body":"Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs\n\nPR Newswire\n\nHONG KONG, Sept. 7, 2026\n\nHONG KONG, Sept. 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672,\n\"Ascletis\") announces that, the ordinary shares of the Company (the \"Shares\"),\nwhich trade on The Stock Exchange of Hong Kong Limited (the \"HK Stock\nExchange\"), have been included in the list of eligible securities under the\nShanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect\n(collectively, the \"Hong Kong Stock Connect\") programs, both with effect from\nSeptember 7, 2026, pursuant to the announcements issued by the Shanghai Stock\nExchange and the Shenzhen Stock Exchange, recently. Following the inclusion of\nthe Shares, eligible investors in Chinese Mainland will be able to trade the\nShares through the Hong Kong Stock Connect channel.\n\nThe Company believes the inclusion of the Shares in the trading mechanism of\nthe Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect\ndemonstrates market recognition of the Company's investment value and growth\nprospects. The Company expects the inclusion of the Shares as eligible\nsecurities will help further expand the shareholder base of the Company,\nincrease the trading liquidity of the Shares, and support the\ninnovation-driven and sustainable growth of the Company in the long term.\n\nAbout the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock\nConnect\n\nThe Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect\nare mutual stock market access mechanisms between Chinese Mainland and the\nHong Kong Special Administrative Region, under which the Shanghai Stock\nExchange and the Shenzhen Stock Exchange have established technical\nconnectivity with the HK Stock Exchange, respectively, to enable investors in\nChinese Mainland and the Hong Kong Special Administrative Region to trade\neligible securities listed on each other's market through their local\nsecurities companies or brokers.\n\nAbout Ascletis Pharma Inc.\n\nAscletis Pharma Inc. is a fully integrated biotechnology company focused on\nthe development and commercialization of potentially best-in-class and\nfirst-in-class therapeutics to treat metabolic diseases. Utilizing its\nproprietary Artificial Intelligence-assisted Structure-Based Drug Discovery\n(AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide\nOral Transport ENhancement Technology (POTENT), Ascletis has developed\nmultiple drug candidates in-house, including both small molecules and\npeptides, such as its lead program, ASC30, a once-daily oral small molecule\nGLP-1R agonist for chronic weight management and diabetes; ASC30_48FDC, a\nonce-daily oral small molecule dual agonist, a fixed dose combination of ASC30\n(GLP-1R agonist) and ASC48 (GIPR agonist), ASC30_48_39FDC, a once-daily oral\nsmall molecule triple agonist, a fixed dose combination of ASC30 (GLP-1R\nagonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)),\nASC39, an eloralintide-like potent selective amylin receptor agonist (SARA)\nonce-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule\ndual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC39\n(amylin receptor agonist (SARA)), ASC36, an amylin peptide, designed to be\nadministered once monthly to once quarterly subcutaneously and once daily\norally, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual\npeptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide\nagonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35\n(GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist,\ndesigned to be administered once monthly subcutaneously and once daily orally,\nand ASC36_37FDC, a once-monthly subcutaneous quadruple peptide agonist, a\nfixed dose combination of ASC36 (amylin receptor agonist) and ASC37\n(GLP-1R/GIPR/GCGR agonist), for chronic weight management. Ascletis is listed\non the Hong Kong Stock Exchange (1672.HK).\n\nFor more information, please visit www.ascletis.com\n(https://www.ascletis.com/) .\n\nContact：\n\nPeter Vozzo\nICR Healthcare\n443-231-0505 (U.S.)\nPeter.vozzo@icrhealthcare.com (mailto:Peter.vozzo@icrhealthcare.com)\n\nAscletis Pharma Inc. PR and IR Teams\n+86-181-0650-9129 (China)\npr@ascletis.com (mailto:pr@ascletis.com)\nir@ascletis.com (mailto:ir@ascletis.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ascletis-announces-inclusion-in-the-hong-kong-stock-connect-list-under-the-shanghai-hong-kong-stock-connect-and-the-shenzhen-hong-kong-stock-connect-programs-302870977.html\n(https://www.prnewswire.com/news-releases/ascletis-announces-inclusion-in-the-hong-kong-stock-connect-list-under-the-shanghai-hong-kong-stock-connect-and-the-shenzhen-hong-kong-stock-connect-programs-302870977.html)\n\nSOURCE Ascletis Pharma Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1810014/Ascletis-Pharma-Logo.jpg?id=OA2932180\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn2ZKBnna-20260907","title":"Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs","author":"PR Newswire","ticker":"1672","created":"2026-09-07T04:15:00.622Z","tickers":["1672"],"exchange":"HKEX","article_body":"Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs\n\nPR Newswire\n\nHONG KONG, Sept. 7, 2026\n\nHONG KONG, Sept. 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672,\n\"Ascletis\") announces that, the ordinary shares of the Company (the \"Shares\"),\nwhich trade on The Stock Exchange of Hong Kong Limited (the \"HK Stock\nExchange\"), have been included in the list of eligible securities under the\nShanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect\n(collectively, the \"Hong Kong Stock Connect\") programs, both with effect from\nSeptember 7, 2026, pursuant to the announcements issued by the Shanghai Stock\nExchange and the Shenzhen Stock Exchange, recently. Following the inclusion of\nthe Shares, eligible investors in Chinese Mainland will be able to trade the\nShares through the Hong Kong Stock Connect channel.\n\nThe Company believes the inclusion of the Shares in the trading mechanism of\nthe Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect\ndemonstrates market recognition of the Company's investment value and growth\nprospects. The Company expects the inclusion of the Shares as eligible\nsecurities will help further expand the shareholder base of the Company,\nincrease the trading liquidity of the Shares, and support the\ninnovation-driven and sustainable growth of the Company in the long term.\n\nAbout the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock\nConnect\n\nThe Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect\nare mutual stock market access mechanisms between Chinese Mainland and the\nHong Kong Special Administrative Region, under which the Shanghai Stock\nExchange and the Shenzhen Stock Exchange have established technical\nconnectivity with the HK Stock Exchange, respectively, to enable investors in\nChinese Mainland and the Hong Kong Special Administrative Region to trade\neligible securities listed on each other's market through their local\nsecurities companies or brokers.\n\nAbout Ascletis Pharma Inc.\n\nAscletis Pharma Inc. is a fully integrated biotechnology company focused on\nthe development and commercialization of potentially best-in-class and\nfirst-in-class therapeutics to treat metabolic diseases. Utilizing its\nproprietary Artificial Intelligence-assisted Structure-Based Drug Discovery\n(AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide\nOral Transport ENhancement Technology (POTENT), Ascletis has developed\nmultiple drug candidates in-house, including both small molecules and\npeptides, such as its lead program, ASC30, a once-daily oral small molecule\nGLP-1R agonist for chronic weight management and diabetes; ASC30_48FDC, a\nonce-daily oral small molecule dual agonist, a fixed dose combination of ASC30\n(GLP-1R agonist) and ASC48 (GIPR agonist), ASC30_48_39FDC, a once-daily oral\nsmall molecule triple agonist, a fixed dose combination of ASC30 (GLP-1R\nagonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)),\nASC39, an eloralintide-like potent selective amylin receptor agonist (SARA)\nonce-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule\ndual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC39\n(amylin receptor agonist (SARA)), ASC36, an amylin peptide, designed to be\nadministered once monthly to once quarterly subcutaneously and once daily\norally, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual\npeptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide\nagonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35\n(GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist,\ndesigned to be administered once monthly subcutaneously and once daily orally,\nand ASC36_37FDC, a once-monthly subcutaneous quadruple peptide agonist, a\nfixed dose combination of ASC36 (amylin receptor agonist) and ASC37\n(GLP-1R/GIPR/GCGR agonist), for chronic weight management. Ascletis is listed\non the Hong Kong Stock Exchange (1672.HK).\n\nFor more information, please visit www.ascletis.com\n(https://www.ascletis.com/) .\n\nContact：\n\nPeter Vozzo\nICR Healthcare\n443-231-0505 (U.S.)\nPeter.vozzo@icrhealthcare.com (mailto:Peter.vozzo@icrhealthcare.com)\n\nAscletis Pharma Inc. PR and IR Teams\n+86-181-0650-9129 (China)\npr@ascletis.com (mailto:pr@ascletis.com)\nir@ascletis.com (mailto:ir@ascletis.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ascletis-announces-inclusion-in-the-hong-kong-stock-connect-list-under-the-shanghai-hong-kong-stock-connect-and-the-shenzhen-hong-kong-stock-connect-programs-302870977.html\n(https://www.prnewswire.com/news-releases/ascletis-announces-inclusion-in-the-hong-kong-stock-connect-list-under-the-shanghai-hong-kong-stock-connect-and-the-shenzhen-hong-kong-stock-connect-programs-302870977.html)\n\nSOURCE Ascletis Pharma Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1810014/Ascletis-Pharma-Logo.jpg?id=OA2932180\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-07T04:15:00.657938206Z","server_sent_at_ms":1788754500657},"received_at":"2026-09-07T04:15:00.716Z","source_url":"https://www.prnewswire.com/news-releases/ascletis-announces-inclusion-in-the-hong-kong-stock-connect-list-under-the-shanghai-hong-kong-stock-connect-and-the-shenzhen-hong-kong-stock-connect-programs-302870977.html"},"analysis":{"id":"125464","press_release_id":"136588","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Ascletis Pharma's ordinary shares (HKEX: 1672) were added to the eligible securities lists for both the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective September 7, 2026.\n\nEligible investors in Chinese Mainland can now trade Ascletis shares through the Stock Connect channel, which the company expects will expand its shareholder base and increase trading liquidity over the long term.\n\nAscletis is a Hong Kong-listed biotech focused on metabolic diseases, with an oral GLP-1 pipeline led by once-daily small-molecule candidate ASC30 for chronic weight management and diabetes.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Southbound Stock Connect access opens a HK-listed oral GLP-1 developer to mainland flows -- watch for a liquidity re-rating rather than a fundamental catalyst."},"keyFigures":{"customDimensions":{"programs":["Shanghai-Hong Kong Stock Connect","Shenzhen-Hong Kong Stock Connect"],"stock_connect_effective_date":"September 7, 2026"}},"quotedText":"demonstrates market recognition of the Company's investment value and growth prospects","namedEntities":{"people":[{"name":"Peter Vozzo","role":"media/IR contact, ICR Healthcare"}],"products":["ASC30","ASC30_48FDC","ASC30_48_39FDC","ASC39","ASC30_39FDC","ASC36","ASC35","ASC36_35FDC","ASC37","ASC36_37FDC"],"companies":[{"name":"Ascletis Pharma Inc.","ticker":"1672","relationship":"filer"},{"name":"The Stock Exchange of Hong Kong Limited","relationship":"listing exchange"},{"name":"Shanghai Stock Exchange","relationship":"Stock Connect partner exchange"},{"name":"Shenzhen Stock Exchange","relationship":"Stock Connect partner exchange"},{"name":"ICR Healthcare","relationship":"IR agency"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Inclusion in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs opens Ascletis shares to mainland Chinese investors, a genuine but gradual liquidity and shareholder-base catalyst. No financial figures, deals, or pipeline events are attached, so it is not market-moving on its own."},"tickerRelevance":{"others":[],"primary":"1672"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap HK-listed biotech","eventGravity":"stock connect inclusion (market access, no financial terms)","sectorWeight":"GLP-1/obesity theme carries elevated retail interest","marketCapAdjustment":"small absolute float impact; gradual southbound flow benefit"}},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Ascletis Pharma's ordinary shares (HKEX: 1672) were added to the eligible securities lists for both the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective September 7, 2026.\n\nEligible investors in Chinese Mainland can now trade Ascletis shares through the Stock Connect channel, which the company expects will expand its shareholder base and increase trading liquidity over the long term.\n\nAscletis is a Hong Kong-listed biotech focused on metabolic diseases, with an oral GLP-1 pipeline led by once-daily small-molecule candidate ASC30 for chronic weight management and diabetes.","key_figures":{"customDimensions":{"programs":["Shanghai-Hong Kong Stock Connect","Shenzhen-Hong Kong Stock Connect"],"stock_connect_effective_date":"September 7, 2026"}},"named_entities":{"people":[{"name":"Peter Vozzo","role":"media/IR contact, ICR Healthcare"}],"products":["ASC30","ASC30_48FDC","ASC30_48_39FDC","ASC39","ASC30_39FDC","ASC36","ASC35","ASC36_35FDC","ASC37","ASC36_37FDC"],"companies":[{"name":"Ascletis Pharma Inc.","ticker":"1672","relationship":"filer"},{"name":"The Stock Exchange of Hong Kong Limited","relationship":"listing exchange"},{"name":"Shanghai Stock Exchange","relationship":"Stock Connect partner exchange"},{"name":"Shenzhen Stock Exchange","relationship":"Stock Connect partner exchange"},{"name":"ICR Healthcare","relationship":"IR agency"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-07T04:16:13.690Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"mid-cap HK-listed biotech","eventGravity":"stock connect inclusion (market access, no financial terms)","sectorWeight":"GLP-1/obesity theme carries elevated retail interest","marketCapAdjustment":"small absolute float impact; gradual southbound flow benefit"}},"durationMs":null,"modelName":"glm-4.7"}}